The Cost-effectiveness of Vitamin Therapy for Age Related Macular Degeneration
This 2007 study simulated the incidence and natural history of age-related macular degeneration (AMD) with and without the use of prophylactic antioxidant vitamin plus zinc supplements to prevent advanced vision threatening disease. The study found that the universal use of vitamin therapy would reduce the percentage of patients with early AMD who ever developed visual impairment in the better-seeing eye to 5.6% compared to 7.0% without such therapy. Compared to no therapy, vitamin therapy cost approximately $21,000 per quality adjusted life (QALY) gained, in 2003 dollars, a cost that was favorable compared to other ocular health interventions.
Incremental Cost-Effectiveness of Vitamin Therapy to Prevent Advanced AMD as Compared to No Therapy
|Cost||Years Visual Impairment and Blindness||Quality-Adjusted|
Life Years (QALYs)
|AMD Costs||Nursing Home Costs||Total|
|Vitamin Therapy for All Diagnosed||720.87||216.51||937.38||0.22501||15.6263|
Rein DB, Saaddine JB, Wittenborn JS, et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology 2007;114(7):1319–1326.
Get email updates
To receive email updates about this page, enter your email address:
- The Vision Health Initiative (VHI)
4770 Buford Highway
Mail Stop K-10
Atlanta, GA 30341-3724
TTY: (888) 232-6348
- Contact CDC-INFO